Cancer therapies often fail to work when tested in clinical trials. As a result, a startling 97 percent of drugs designed for specific cancer treatments do not receive approval from the Food and Drug Administration. Now researchers say they may have figured out part of the reason why.
In a new study out Wednesday in the journal Science Translational Medicine, scientists report many cancer drugs don’t work the way their designers assumed they did. The dis